According to recent research, it is feasible to create PROTACs that specifically target GPCRs linked to cancer, such as the estrogen receptor (ER) in breast cancer and the AR in prostate cancer, leading to strong anti‐tumor effects in preclinical models [292]. Here, AR is linked to prostate cancer.